-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6

Benzinga·09/14/2026 10:42:44
语音播报
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.